Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS-936558, ONO-4538) in patients with...
-
Upload
betty-boyd -
Category
Documents
-
view
235 -
download
4
Transcript of Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS-936558, ONO-4538) in patients with...
![Page 1: Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS-936558, ONO-4538) in patients with platinum-resistant ovarian cancer Presented By Junzo Hamanishi.](https://reader036.fdocuments.net/reader036/viewer/2022062304/56649f1e5503460f94c3599b/html5/thumbnails/1.jpg)
Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS-936558, ONO-4538) in patients with platinum-resistant ovarian cancer
Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting
![Page 2: Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS-936558, ONO-4538) in patients with platinum-resistant ovarian cancer Presented By Junzo Hamanishi.](https://reader036.fdocuments.net/reader036/viewer/2022062304/56649f1e5503460f94c3599b/html5/thumbnails/2.jpg)
PD-1/ PD-L1 pathway in suppressing anti-tumor immunity
Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting
![Page 3: Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS-936558, ONO-4538) in patients with platinum-resistant ovarian cancer Presented By Junzo Hamanishi.](https://reader036.fdocuments.net/reader036/viewer/2022062304/56649f1e5503460f94c3599b/html5/thumbnails/3.jpg)
Slide 3
Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting
![Page 4: Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS-936558, ONO-4538) in patients with platinum-resistant ovarian cancer Presented By Junzo Hamanishi.](https://reader036.fdocuments.net/reader036/viewer/2022062304/56649f1e5503460f94c3599b/html5/thumbnails/4.jpg)
Nivolumab <br />(ONO4538/BMS936558)
Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting
![Page 5: Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS-936558, ONO-4538) in patients with platinum-resistant ovarian cancer Presented By Junzo Hamanishi.](https://reader036.fdocuments.net/reader036/viewer/2022062304/56649f1e5503460f94c3599b/html5/thumbnails/5.jpg)
Study design: Investigator initiated, 2 cohorts Phase II
Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting
![Page 6: Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS-936558, ONO-4538) in patients with platinum-resistant ovarian cancer Presented By Junzo Hamanishi.](https://reader036.fdocuments.net/reader036/viewer/2022062304/56649f1e5503460f94c3599b/html5/thumbnails/6.jpg)
Key inclusion criteria
Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting
![Page 7: Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS-936558, ONO-4538) in patients with platinum-resistant ovarian cancer Presented By Junzo Hamanishi.](https://reader036.fdocuments.net/reader036/viewer/2022062304/56649f1e5503460f94c3599b/html5/thumbnails/7.jpg)
Study schedule
Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting
![Page 8: Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS-936558, ONO-4538) in patients with platinum-resistant ovarian cancer Presented By Junzo Hamanishi.](https://reader036.fdocuments.net/reader036/viewer/2022062304/56649f1e5503460f94c3599b/html5/thumbnails/8.jpg)
Demographics
Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting
![Page 9: Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS-936558, ONO-4538) in patients with platinum-resistant ovarian cancer Presented By Junzo Hamanishi.](https://reader036.fdocuments.net/reader036/viewer/2022062304/56649f1e5503460f94c3599b/html5/thumbnails/9.jpg)
Adverse events: Regardless of causality <br /> (>=4 patients)
Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting
![Page 10: Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS-936558, ONO-4538) in patients with platinum-resistant ovarian cancer Presented By Junzo Hamanishi.](https://reader036.fdocuments.net/reader036/viewer/2022062304/56649f1e5503460f94c3599b/html5/thumbnails/10.jpg)
Slide 10
Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting
![Page 11: Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS-936558, ONO-4538) in patients with platinum-resistant ovarian cancer Presented By Junzo Hamanishi.](https://reader036.fdocuments.net/reader036/viewer/2022062304/56649f1e5503460f94c3599b/html5/thumbnails/11.jpg)
Serious adverse events<br />(Treatment-related)
Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting
![Page 12: Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS-936558, ONO-4538) in patients with platinum-resistant ovarian cancer Presented By Junzo Hamanishi.](https://reader036.fdocuments.net/reader036/viewer/2022062304/56649f1e5503460f94c3599b/html5/thumbnails/12.jpg)
Clinical Effect : Best Overall Response
Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting
![Page 13: Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS-936558, ONO-4538) in patients with platinum-resistant ovarian cancer Presented By Junzo Hamanishi.](https://reader036.fdocuments.net/reader036/viewer/2022062304/56649f1e5503460f94c3599b/html5/thumbnails/13.jpg)
A Responder with Serous adenoca : <br />Nivolumab 3mg/kg
Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting
![Page 14: Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS-936558, ONO-4538) in patients with platinum-resistant ovarian cancer Presented By Junzo Hamanishi.](https://reader036.fdocuments.net/reader036/viewer/2022062304/56649f1e5503460f94c3599b/html5/thumbnails/14.jpg)
A Responder with Clear cell carcinoma :<br />Nivolumab 3mg/kg
Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting
![Page 15: Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS-936558, ONO-4538) in patients with platinum-resistant ovarian cancer Presented By Junzo Hamanishi.](https://reader036.fdocuments.net/reader036/viewer/2022062304/56649f1e5503460f94c3599b/html5/thumbnails/15.jpg)
Best overall responses in all patients
Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting
![Page 16: Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS-936558, ONO-4538) in patients with platinum-resistant ovarian cancer Presented By Junzo Hamanishi.](https://reader036.fdocuments.net/reader036/viewer/2022062304/56649f1e5503460f94c3599b/html5/thumbnails/16.jpg)
Best overall responses in all patients in 2 cohorts
Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting
![Page 17: Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS-936558, ONO-4538) in patients with platinum-resistant ovarian cancer Presented By Junzo Hamanishi.](https://reader036.fdocuments.net/reader036/viewer/2022062304/56649f1e5503460f94c3599b/html5/thumbnails/17.jpg)
Summary
Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting
![Page 18: Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS-936558, ONO-4538) in patients with platinum-resistant ovarian cancer Presented By Junzo Hamanishi.](https://reader036.fdocuments.net/reader036/viewer/2022062304/56649f1e5503460f94c3599b/html5/thumbnails/18.jpg)
Conclusions
Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting
![Page 19: Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS-936558, ONO-4538) in patients with platinum-resistant ovarian cancer Presented By Junzo Hamanishi.](https://reader036.fdocuments.net/reader036/viewer/2022062304/56649f1e5503460f94c3599b/html5/thumbnails/19.jpg)
Acknowledgements
Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting
![Page 20: Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS-936558, ONO-4538) in patients with platinum-resistant ovarian cancer Presented By Junzo Hamanishi.](https://reader036.fdocuments.net/reader036/viewer/2022062304/56649f1e5503460f94c3599b/html5/thumbnails/20.jpg)
Research group
Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting
![Page 21: Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS-936558, ONO-4538) in patients with platinum-resistant ovarian cancer Presented By Junzo Hamanishi.](https://reader036.fdocuments.net/reader036/viewer/2022062304/56649f1e5503460f94c3599b/html5/thumbnails/21.jpg)
Slide 21
Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting
![Page 22: Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS-936558, ONO-4538) in patients with platinum-resistant ovarian cancer Presented By Junzo Hamanishi.](https://reader036.fdocuments.net/reader036/viewer/2022062304/56649f1e5503460f94c3599b/html5/thumbnails/22.jpg)
Clinical Effect : Response Duration
Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting
![Page 23: Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS-936558, ONO-4538) in patients with platinum-resistant ovarian cancer Presented By Junzo Hamanishi.](https://reader036.fdocuments.net/reader036/viewer/2022062304/56649f1e5503460f94c3599b/html5/thumbnails/23.jpg)
Best overall responses in all patients
Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting
![Page 24: Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS-936558, ONO-4538) in patients with platinum-resistant ovarian cancer Presented By Junzo Hamanishi.](https://reader036.fdocuments.net/reader036/viewer/2022062304/56649f1e5503460f94c3599b/html5/thumbnails/24.jpg)
Slide 24
Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting